Advanced search
Publication Cover
Pharmacogenomics Volume 13, 2012 - Issue 16
Submit an article Journal homepage
266
Views
0
CrossRef citations to date
0
Altmetric
Case Report

Pharmacogenetics and Beyond: Variability of Voriconazole Plasma Levels in a Patient with Primary Immunodeficiency

Julie Autmizguine1 Infectious Diseases Division, CHU Sainte-Justine – University of Montreal, Montreal (QC), Canada;2 Department of Pediatrics, CHU Sainte-Justine – University of Montreal, Montreal (QC), Canada
,
Maja Krajinovic2 Department of Pediatrics, CHU Sainte-Justine – University of Montreal, Montreal (QC), Canada;3 Clinical Pharmacology Unit, CHU Sainte-Justine – University of Montreal, Montreal (QC), Canada;4 Research Center, CHU Sainte-Justine – University of Montreal, Montreal (QC), Canada;5 Department of Pharmacology, University of Montreal, Montreal (QC), Canada
,
Julie Rousseau4 Research Center, CHU Sainte-Justine – University of Montreal, Montreal (QC), Canada
,
Yves Théorêt3 Clinical Pharmacology Unit, CHU Sainte-Justine – University of Montreal, Montreal (QC), Canada;4 Research Center, CHU Sainte-Justine – University of Montreal, Montreal (QC), Canada;5 Department of Pharmacology, University of Montreal, Montreal (QC), Canada
,
Catherine Litalien2 Department of Pediatrics, CHU Sainte-Justine – University of Montreal, Montreal (QC), Canada;3 Clinical Pharmacology Unit, CHU Sainte-Justine – University of Montreal, Montreal (QC), Canada;4 Research Center, CHU Sainte-Justine – University of Montreal, Montreal (QC), Canada;5 Department of Pharmacology, University of Montreal, Montreal (QC), Canada
,
Christopher Marquis6 Department of Pharmacy, CHU Sainte-Justine – University of Montreal, Montreal (QC), Canada
,
Bruce Tapiéro1 Infectious Diseases Division, CHU Sainte-Justine – University of Montreal, Montreal (QC), Canada;2 Department of Pediatrics, CHU Sainte-Justine – University of Montreal, Montreal (QC), Canada;4 Research Center, CHU Sainte-Justine – University of Montreal, Montreal (QC), Canada
&
Philippe Ovetchkine1 Infectious Diseases Division, CHU Sainte-Justine – University of Montreal, Montreal (QC), Canada;2 Department of Pediatrics, CHU Sainte-Justine – University of Montreal, Montreal (QC), Canada;3 Clinical Pharmacology Unit, CHU Sainte-Justine – University of Montreal, Montreal (QC), Canada;4 Research Center, CHU Sainte-Justine – University of Montreal, Montreal (QC), CanadaCorrespondence[email protected]
 show all
Pages 1961-1965 | Published online: 10 Dec 2012

References

  • Gallin JI , AllingDW, MalechHL et al. Itraconazole to prevent fungal infections in chronic granulomatous disease. N. Engl. J. Med. 348(24) , 2416–2422 (2003).
  • Walsh TJ , AnaissieEJ, DenningDW et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin. Infect. Dis. 46(3) , 327–360 (2008).
  • Pascual A , CalandraT, BolayS, BuclinT, BilleJ, MarchettiO. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin. Infect. Dis.46(2) , 201–211 (2008).
  • Goldstein B , GiroirB, RandolphA. International pediatric sepsis consensus conference: definitions for sepsis and organ dysfunction in pediatrics. Pediatr. Crit. Care Med.6(1) , 2–8 (2005).
  • Smith J , SafdarN, KnasinskiV et al. Voriconazole therapeutic drug monitoring. Antimicrob. Agents Chemother. 50(4) , 1570–1572 (2006).
  • Andes D , PascualA, MarchettiO. Antifungal therapeutic drug monitoring: established and emerging indications. Antimicrob. Agents Chemother.53(1) , 24–34 (2009).
  • Okano M , YamadaM, OhtsuM et al. Successful treatment with methylprednisolone pulse therapy for a life-threatening pulmonary insufficiency in a patient with chronic granulomatous disease following pulmonary invasive aspergillosis and Burkholderia cepacia infection. Respiration 66(6) , 551–554 (1999).
  • Eiden C , CociglioM, Hillaire-BuysD et al. Pharmacokinetic variability of voriconazole and N-oxide voriconazole measured as therapeutic drug monitoring. Xenobiotica 40(10) , 701–706.
  • Hassan A , BurhenneJ, RiedelKD et al. Modulators of very low voriconazole concentrations in routine therapeutic drug monitoring. Ther. Drug Monit. 33(1) , 86–93 (2011).
  • Bourgeois S , LabudaD. Dynamic allele-specific oligonucleotide hybridization on solid support. Anal Biochem.324(2) , 309–311 (2004).
  • Baldwin RM , OhlssonS, PedersenRS et al. Increased omeprazole metabolism in carriers of the CYP2C19*17 allele; a pharmacokinetic study in healthy volunteers. Br. J. Clin. Pharmacol. 65(5) , 767–774 (2008).
  • Hulot JS , BuraA, VillardE et al. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 108(7) , 2244–2247 (2006).
  • Yanni SB , AnnaertPQ, AugustijnsP, IbrahimJG, BenjaminDK Jr, Thakker DR. In vitro hepatic metabolism explains higher clearance of voriconazole in children versus adults: role of CYP2C19 and flavin-containing monooxygenase 3. Drug Metab. Dispos.38(1) , 25–31 (2010).
  • Weiss J , Ten Hoevel MM, Burhenne J et al.CYP2C19 genotype is a major factor contributing to the highly variable pharmacokinetics of voriconazole. J. Clin. Pharmacol.49(2) , 196–204 (2009).
  • Wang G , LeiHP, LiZ et al. The CYP2C19 ultra-rapid metabolizer genotype influences the pharmacokinetics of voriconazole in healthy male volunteers. Eur. J. Clin. Pharmacol. 65(3) , 281–285 (2009).
  • Li XQ , AnderssonTB, AhlstromM, WeidolfL. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab. Dispos.32(8) , 821–827 (2004).
  • Carcillo JA , DoughtyL, KofosD et al. Cytochrome P450 mediated-drug metabolism is reduced in children with sepsis-induced multiple organ failure. Intensive Care Med. 29(6) , 980–984 (2003).
  • Aitken AE , MorganET. Gene-specific effects of inflammatory cytokines on cytochrome P450 2C, 2B6 and 3A4 mRNA levels in human hepatocytes. Drug Metab. Dispos.35(9) , 1687–1693 (2007).
  • Chen Y , FergusonSS, NegishiM, GoldsteinJA. Identification of constitutive androstane receptor and glucocorticoid receptor binding sites in the CYP2C19 promoter. Mol. Pharmacol.64(2) , 316–324 (2003).
  • Seger RA , GungorT, BelohradskyBH et al. Treatment of chronic granulomatous disease with myeloablative conditioning and an unmodified hemopoietic allograft: a survey of the European experience, 1985–2000. Blood 100(13) , 4344–4350 (2002).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.